For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Zevra Therapeutics Inc’s stock clocked out at $7.08, down -3.93% from its previous closing price of $7.37. In other words, the price has decreased by -$3.93 from its previous closing price. On the day, 1.31 million shares were traded. ZVRA stock price reached its highest trading level at $7.35 during the session, while it also had its lowest trading level at $6.63.
Ratios:
To gain a deeper understanding of ZVRA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.00 and its Current Ratio is at 2.00. In the meantime, Its Debt-to-Equity ratio is 1.83 whereas as Long-Term Debt/Eq ratio is at 1.81.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Maxim Group on April 02, 2024, Reiterated its Buy rating but revised its target price to $18 from $12 previously.
On March 17, 2023, Maxim Group started tracking the stock assigning a Buy rating and target price of $12.Maxim Group initiated its Buy rating on March 17, 2023, with a $12 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jul 17 ’24 when Clifton R. LaDuane bought 2,000 shares for $6.77 per share. The transaction valued at 13,540 led to the insider holds 18,469 shares of the business.
Anderson Thomas bought 10,000 shares of ZVRA for $68,065 on Jul 16 ’24. The Director now owns 20,000 shares after completing the transaction at $6.81 per share. On Jul 12 ’24, another insider, Bode John B, who serves as the Director of the company, bought 10,000 shares for $5.87 each. As a result, the insider paid 58,661 and bolstered with 30,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZVRA now has a Market Capitalization of 372534016 and an Enterprise Value of 382743936. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.53 while its Price-to-Book (P/B) ratio in mrq is 9.15. Its current Enterprise Value per Revenue stands at 16.157 whereas that against EBITDA is -5.404.
Stock Price History:
Over the past 52 weeks, ZVRA has reached a high of $8.44, while it has fallen to a 52-week low of $3.89. The 50-Day Moving Average of the stock is 24.80%, while the 200-Day Moving Average is calculated to be 30.85%.
Shares Statistics:
It appears that ZVRA traded 683.46K shares on average per day over the past three months and 1205510 shares per day over the past ten days. A total of 52.62M shares are outstanding, with a floating share count of 52.20M. Insiders hold about 0.79% of the company’s shares, while institutions hold 30.57% stake in the company. Shares short for ZVRA as of 1722384000 were 4397553 with a Short Ratio of 6.43, compared to 1719532800 on 2958052. Therefore, it implies a Short% of Shares Outstanding of 4397553 and a Short% of Float of 10.5500005.
